Treating smooth muscle hyperactivity with (R)-oxybutynin and (R)-desethyloxybutynin

Abstract

The optically pure R(-)-isomer of oxybutynin and the optically pure R(-)-isomer of desethyl-oxybutynin, which are substantially free of the corresponding S(+)-isomers, are potent anticholinergic spasmolytics, useful for relief of symptoms associated with urinary bladder smooth muscle hyperactivity, such as Urinary Incontinence and gastrointestinal smooth muscle hyperactivity, such as Irritable Bowel Syndrome. Methods are disclosed utilizing the optically pure R(-)-isomers of oxybutynin and desethyloxybutynin for treating cholinergically mediated smooth muscle hyperactivity while minimizing the side effects associated with administration of racemic oxybutynin or racemic desethyloxybutynin.

Description

technical field [0001] The present invention relates to the optically active R(-)-isomer of 4-diethylamino-2-butynylcyclohexylphenyl glycolate and its name R(-)-4-ethylamino-2-butan Optically active metabolite of alkynylcyclohexylphenylglycolate. The compound 4-diethylamino-2-butynylcyclohexylphenyl glycolate, whose common name is oxybutynin (OXY), is an approved drug for the treatment of urinary incontinence and the treatment of gastrointestinal smooth muscle function Hyperactivity is also effective. [0002] The oxybutynin (OXY) compound 4-ethylamino-2-butynylcyclohexylphenyl glycolate is known as desethyloxybutynin (DEO) and has the following chemical structure: [0003] Desethyloxybutynin (DEO) Background technique [0004] Racemic oxybutynin (OXY) is used therapeutically for the treatment of smooth muscle hyperactivity, such as urinary incontinence. OXY exerts its antispasmodic effect by inhibiting the ...

AI Technical Summary

Problems solved by technology

N-Oxybutynin is a therapeutically active compound but may not be chemically stable (Lindeke et al., 1981)